The International Biotechnology Center “Generium”, (LLC IBC Generium) is a private scientific research company, established in May 2011. The idea of a National Research Center is to bring together leading Russian scientists, including those living abroad, professionals with advanced skills and cutting-edge scientific knowledge to work on discovery and development of innovative biotechnology-based therapeutics. This idea belongs to the scientist and entrepreneur with over 20 years of experience in the domestic pharmaceutical industry, Alexander Mikhailovich Schuster.
His idea has turned into reality in the partnership with the largest Russian pharmaceutical company OJSC “Pharmstandard” and their “Technopark project” (“Nauchtechstroy Plus” LLC) under the leadership of Kharitonin V. V.
Our Mission is the development and manufacturing application of innovative, effective and safe medical products.
The first successes of our Holding have been recognized by prestigious Awards, high honours and received a wide recognition in Russia.
In 2012 the team of professionals led by Schuster A. M. (the Chairman of the Board of Directors of OJSC “Generium” and LLC IBC Generium), together with Paltsev M. A. (an acting member of the Russian Academy of Sciences) has received the Prize of the Government of the Russian Federation in the field of Science and Technology.
This prestigious Award was granted for the development and manufacturing application of our innovative diagnostic product Diaskintest®, which is an efficient and extremely reliable test for identification of patients with active tuberculosis and latent TB infection. Diaskintest® was introduced into the stardard medical practice in Russia and used for the regular population screening for tuberculosis infection. The results of this screenening have demonstrated the superior efficiency and accuracy of this novel diagnistic test that allowed the precise identification and timely treatment of the individual carriers of this deadly disease, among thousands of screened individuals.
Therefore this novel, highly sensitive and specific diagnostic tool has helped to substantially reduce the State budget of the Russian Federation and get rid of the old and inefficient subcutaneous tuberculin diagnostic test, (known as the Mantoux test).
The research and development program of the LLC IBC Generium has actively incorporated the principles of the “Pharma Strategy 2020” program, established by the Government of the Russian Federation in 2009. Our company’s portfolio primarily includes medical products from the list of vital and essential drugs, as well as from the list of strategically important drugs, approved by the Government of the Russian Federation. It is mandated by the State that the manufacturing of those medical products would be organized in the Russian Federation.
Our Company’s strategy is to gradually transition from the generic drugs to the discovery and development of novel therapeutics. At this point, 30% of our company’s portfolio consists of the original innovative medical products that are unique on the World’s pharmaceutical market.
The proceseedings from sales of our generic drugs are invested in the research and development efforts of our company, for discovery and development of innovative therapies with the goal to bring cutting-edge technologies and state-of-the-art science to Russia, which is essential for the development of new generations of safe and effective drugs.
Our pipeline includes a variety of generic as well as innovative medical products for the broad spectrum of diseases and therapeutic areas, like oncology, cardiology and angiology, neurology, gynaecology, infectious diseases, diseases of the joints, and rare (orphan) diseases.
We collaborate with the leading experts in the biotechnology field and companies from Denmark, Switzerland, Cuba, Israel, France, Germany and USA.
IBC Generium is a scientific research company with a mission to develop safe and effective biotechnology-based medical products and cell-based technologies to the stage of industrial application. Our highly qualified scientific staff and state-of-the-art facilities allow us to design and develop virtually any recombinant protein, monoclonal antibody or cell-based product, suitable for industrial manufacturing, preclinical and clinical studies.
We draw our ideas for novel and generic medical products from the products developed by our own company as well as those of others in the biotech and pharmaceutical industry, suitable for licensing in the Russian Federation. The main condition for licensing of the medicinal product or cell-based technology is the ability to organize the full cycle manufacturing of this product and transfer all the necessary technological know-how to the Russian Federation.
Our Scientific Expertise
- Molecular and cell biology, immunology.
- Cell line development, upstream process optimization for pilot scale cultivation.
- Development and optimization of small- and large-scale technological processes for isolation and analysis of therapeutic recombinant proteins, monoclonal antibodies and peptides.
- Industrial production of recombinant proteins based in mammalian and bacterial cells.
- Clinical research.
A professional, highly qualified team is a prerequisite for success of the “Generium” project.
Continuing professional education and recruitment of promising young professionals are the top priorities for Our Company.
The key elements of the corporate system of training and selection are:
- training in foreign biotechnology companies and academic institutions;
- training and master classes by leading scientists of the IBC Generium;
- establishment of a scientific and educational center with Vladimir State University named after A. G. and N. G. Stoletovs;
- participation in the most important Russian and international conferences and symposiums.